Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases

European Journal of Cancer

Volumn 47, Issue 2, 2011, Pages 277-286

  Merz, Maximilian ^a   Komljenovic, Dorde ^a   Zwick, Stefan ^b   Semmler, Wolfhard ^a   Bäuerle, Tobias ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Angiogenesis; Bone metastases; Diffusion weighted imaging; Dynamic contrast enhanced MRI; Paclitaxel; Sorafenib tosylate; Vessel remodelling; Vessel size imaging

Indexed keywords

GADOLINIUM PENTETATE; PACLITAXEL; SORAFENIB; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG EFFECT; DRUG POTENCY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MONOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE RAT; OSTEOLYSIS; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; FEMALE; HUMANS; PACLITAXEL; PYRIDINES; RATS; RATS, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650712546     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.08.019     Document Type: Article

References (29)

1. T.A. Plunkett, P. Smith, and R.D. Rubens Risk of complications from bone metastases in breast cancer. Implications for management Eur J Cancer 36 4 2000 476 482
2. R.E. Coleman Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 12 20 Pt 2 2006 6243s 6249s
3. J.J. Body Breast cancer: bisphosphonate therapy for metastatic bone disease Clin Cancer Res 12 20 Pt 2 2006 6258s 6263s
4. J. Folkman Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 6 Suppl 16 2002 15 18
5. J. Folkman Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis New Engl J Med 333 26 1995 1757 1763
6. L.K. Dunn, K.S. Mohammad, and P.G. Fournier Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment PLoS One 4 9 2009 e6896
7. M. Nakagawa, T. Kaneda, and T. Arakawa Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts FEBS Lett 473 2 2000 161 164
8. T. Bäuerle, H. Hilbig, and S. Bartling Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI Neoplasia 10 5 2008 511 520
9. T. Bäuerle, M. Merz, D. Komljenovic, S. Zwick, and W. Semmler Drug induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced MRI and vessel size imaging - a longitudinal in vivo study Clin Cancer Res 16 12 2010 3215 3225
10. S. Wilhelm, C. Carter, and M. Lynch Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat Rev Drug Discov 5 10 2006 835 844
11. S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 19 2004 7099 7109
12. R.K. Jain, D.G. Duda, and C.G. Willett Biomarkers of response and resistance to antiangiogenic therapy Nat Rev Clin Oncol 6 6 2009 327 338
13. I. Tropres, S. Grimault, and A. Vaeth Vessel size imaging Magn Reson Med 45 3 2001 397 408
14. S. Zwick, R. Strecker, and V. Kiselev Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging J Magn Reson Imaging 29 5 2009 1125 1133
15. K.C. Lee, S. Sud, and C.R. Meyer An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone Cancer Res 67 8 2007 3524 3528
16. T. Bäuerle, H. Adwan, and F. Kiessling Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein Int J Cancer 115 2 2005 177 186
17. G. Brix, W. Semmler, and R. Port Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging J Comput Assist Tomogr 15 4 1991 621 628
18. A.M. Herneth, S. Guccione, and M. Bednarski Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization Eur J Radiol 45 3 2003 208 213
19. F. Kiessling, M. Jugold, E.C. Woenne, and G. Brix Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging Eur Radiol 17 8 2007 2136 2148
20. L.E. Benjamin, D. Golijanin, A. Itin, D. Pode, and E. Keshet Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal J Clin Invest 103 2 1999 159 165
21. T.L. Andersen, T.E. Sondergaard, and K.E. Skorzynska A physical mechanism for coupling bone resorption and formation in adult human bone Am J Pathol 174 1 2009 239 247
22. S.P. Luckman, D.E. Hughes, and F.P. Coxon Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras J Bone Miner Res 13 4 1998 581 589
23. H. Peng, Y. Sohara, and R.A. Moats The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation Cancer Res 67 19 2007 9346 9355
24. A. Strube, J. Hoffmann, and E. Stepina Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption Clin Cancer Res 15 11 2009 3751 3759
25. D. Belotti, V. Vergani, and T. Drudis The microtubule-affecting drug paclitaxel has antiangiogenic activity Clin Cancer Res 2 11 1996 1843 1849
26. E.L. Schwartz Antivascular actions of microtubule-binding drugs Clin Cancer Res 15 8 2009 2594 2601
27. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer New Engl J Med 357 26 2007 2666 2676
28. E. Naumova, P. Ubezio, and A. Garofalo The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis Clin Cancer Res 12 6 2006 1839 1849
29. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 5706 2005 58 62